Company profile

Haisco Pharmaceutical Group

Diversified pharma

002653 · SZSE · China

Public Market Listing

002653SZSE

SZSE primary exchange listing

Live quotes, historical charts, and market capitalization for Haisco Pharmaceutical Group are available on Yahoo Finance.

External market data link · No third-party exchange redistribution

Assets

(9 total)

9Total Assets

0Approved

5Phase 3 / Filed

4Phase 1–2 / Early

8Diseases

Showing 9 of 9 assets

		Target & Modality
Anrikefon (HSK21542)	Phase 3	Kappa-opioid receptor (agonist, peripherally restricted)Small molecule	Chronic Kidney Disease
Crisugabalin	Phase 3	α2δ-1 subunit of voltage-gated calcium channelsSmall molecule	Diabetic Peripheral Neuropathic Pain
HSK39004	Phase 3	Phosphodiesterase 3 and Phosphodiesterase 4 (PDE3/PDE4)Small molecule	Chronic Obstructive Pulmonary Disease
HSK44459	Phase 3	PDE4BSmall molecule	Atopic DermatitisPsoriasis
HSK7653	Phase 3	GLP-1 receptorSmall molecule	Type 2 Diabetes
HSK47388	Phase 2	IL-23 receptorSmall molecule	Inflammatory Bowel DiseasePsoriasis Ulcerative Colitis
HSK40118	Phase 1	EGFRSmall molecule	Non-Small Cell Lung Cancer
HSK41959	Phase 1	MAT2ASmall molecule	Non-Small Cell Lung Cancer
Cofrogliptin	Preclinical / Unstaged	DPP-4Small molecule	Type 2 Diabetes

Research

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Research

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.